Evidence map›Paper›PMID 33096866›Full record

ArticleMedical sciences (Basel, Switzerland)2020

Treatment of C3 Glomerulopathy in Adult Kidney Transplant Recipients: A Systematic Review.

Maria L Gonzalez Suarez, Charat Thongprayoon, Panupong Hansrivijit, Karthik Kovvuru, Swetha R Kanduri, Narothama R Aeddula, Aleksandra I Pivovarova, Api Chewcharat, Tarun Bathini, Michael A Mao and 2 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Medical sciences (Basel, Switzerland), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. A Narrative Review of C3 Glomerulopathy: From Pathogenesis to Targeted Therapy.Canadian journal of kidney health and disease · 2026
    Review
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Monogenic Kidney Diseases in Kidney Transplantation.Kidney international reports · 2024
    Review
  16. Article
  17. Article
  18. Review
  19. Review
  20. C3 glomerulopathy: Understanding an ultra-rare complement-mediated renal disease.American journal of medical genetics. Part C, Seminars in medical genetics · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 9 institutions in 1 country.

Maria L Gonzalez SuarezDivision of Nephrology, Department of Internal Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA.ORCID 0000-0002-8930-4611
Charat ThongprayoonDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Rochester, MN 55905, USA.
Panupong HansrivijitDepartment of Internal Medicine, University of Pittsburgh Medical Center Pinnacle, Harrisburg, PA 17101, USA.ORCID 0000-0002-5041-4290
Karthik KovvuruDepartment of Medicine, Ochsner Medical Center, New Orleans, LA 70121, USA.
Swetha R KanduriDepartment of Medicine, Ochsner Medical Center, New Orleans, LA 70121, USA.ORCID 0000-0002-7190-6665
Narothama R AeddulaDivision of Nephrology, Department of Medicine, Deaconess Health System, Evansville, IN 47710, USA.ORCID 0000-0001-8530-668X
Aleksandra I PivovarovaDivision of Nephrology, Department of Internal Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA.ORCID 0000-0002-1335-7696
Api ChewcharatDepartment of Medicine, Mount Auburn Hospital, Harvard Medical School, Cambridge, MA 02138, USA.ORCID 0000-0002-1707-9988
Tarun BathiniDepartment of Internal Medicine, University of Arizona, Tucson, AZ 85721, USA.
Michael A MaoDivision of Nephrology and Hypertension, Department of Medicine, Mayo Clinic, Jacksonville, FL 32224, USA.ORCID 0000-0003-1814-7003
Arpita BasuEmory Transplant Center and Department of Medicine, Renal Division, Emory University School of Medicine, Atlanta, GA 30322, USA.ORCID 0000-0002-0533-4582
Wisit CheungpasitpornDivision of Nephrology, Department of Internal Medicine, University of Mississippi Medical Center, Jackson, MS 39216, USA.ORCID 0000-0001-9954-9711
Mayo Clinic · USOchsner Medical Center · USDeaconess Hospital · USEmory University · USMayo Clinic in Florida · USMount Auburn Hospital · USUniversity of Arizona · USUniversity of Mississippi Medical Center · USUPMC Central Pa · US

Funding

Tracking and Evaluation CoreU54GM115428 · NIGMS · UNIVERSITY OF MISSISSIPPI MED CTR · PI COMPRETTA, CAROLINE E. · 2016 to 2025
$38.2M
NIGMS NIH HHS U54 GM115428
6 · The paper itself

Abstract

backgroundC3 glomerulopathy (C3G), a rare glomerular disease mediated by alternative complement pathway dysregulation, is associated with a high rate of recurrence and graft loss after kidney transplantation (KTx). We aimed to assess the efficacy of different treatments for C3G recurrence after KTx.

methodsDatabases (MEDLINE, EMBASE, and Cochrane Database) were searched from inception through 3 May, 2019. Studies were included that reported outcomes of adult KTx recipients with C3G. Effect estimates from individual studies were combined using the random-effects, generic inverse variance method of DerSimonian and Laird., The protocol for this meta-analysis is registered with PROSPERO (no. CRD42019125718).

resultsTwelve studies (7 cohort studies and 5 case series) consisting of 122 KTx patients with C3G (73 C3 glomerulonephritis (C3GN) and 49 dense deposit disease (DDD)) were included. The pooled estimated rates of allograft loss among KTx patients with C3G were 33% (95% CI: 12-57%) after eculizumab, 42% (95% CI: 2-89%) after therapeutic plasma exchange (TPE), and 81% (95% CI: 50-100%) after rituximab. Subgroup analysis based on type of C3G was performed. Pooled estimated rates of allograft loss in C3GN KTx patients were 22% (95% CI: 5-46%) after eculizumab, 56% (95% CI: 6-100%) after TPE, and 70% (95% CI: 24-100%) after rituximab. Pooled estimated rates of allograft loss in DDD KTx patients were 53% (95% CI: 0-100%) after eculizumab. Data on allograft loss in DDD after TPE (1 case series, 0/2 (0%) allograft loss at 6 months) and rituximab (1 cohort, 3/3 (100%) allograft loss) were limited. Among 66 patients (38 C3GN, 28 DDD) who received no treatment (due to stable allograft function at presentation and/or clinical judgment of physicians), pooled estimated rates of allograft loss were 32% (95% CI: 7-64%) and 53% (95% CI: 28-77%) for C3GN and DDD, respectively. Among treated C3G patients, data on soluble membrane attack complex of complement (sMAC) were limited to patients treated with eculizumab (N = 7). 80% of patients with elevated sMAC before eculizumab responded to treatment. In addition, all patients who responded to eculizumab had normal sMAC levels after post-eculizumab.

conclusionsOur study suggests that the lowest incidence of allograft loss (33%) among KTX patients with C3G are those treated with eculizumab. Among those who received no treatment for C3G due to stable allograft function, there is a high incidence of allograft loss of 32% in C3GN and 53% in DDD. sMAC level may help to select good responders to eculizumab.

Indexed as

C3 glomerulonephritisC3 glomerulopathydense deposit diseasekidney transplantationrenal transplantation

Identifiers

PMID33096866
PMCPMC7712822
OpenAlexW3093760076

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.